Marc Grasso

Marc Grasso's Title

Marc Grasso currently holds the position of Chief Financial Officer (CFO). With a robust background in both finance and the life sciences sector, he brings a unique blend of expertise to his role. His responsibilities likely include overseeing financial planning, risk management, and financial reporting, ensuring the company's fiscal health and strategic growth.

Marc Grasso's Education and Expertise

Marc Grasso has a distinguished educational background, having received his M.D. from the Johns Hopkins University School of Medicine, where he also conducted research in molecular oncology. He also holds an A.B. in molecular biology with honors from Princeton University. His academic credentials are complemented by his extensive expertise in biotechnology and life sciences, making him a well-rounded expert in both the medical and financial dimensions of the industry.

Marc Grasso's Achievements

Throughout his career, Marc Grasso has held several high-profile positions that underscore his achievements in the financial and biotechnology sectors. Notably, he served as Chief Financial Officer and Chief Business Officer at Kura Oncology, Inc., where he played a pivotal role in the company's financial strategy and business development. At Stifel, he was responsible for building and managing the west coast life sciences and biotechnology investment banking business. His achievements also include significant contributions to the expansion of Leerink Swann's west coast franchise in the biotechnology sector.

Marc Grasso's Experience

Marc Grasso boasts a wealth of experience in the investment banking and healthcare sectors. He was Managing Director of Investment Banking in the Global Healthcare Group at UBS, focusing on the biotechnology sector. His tenure at Leerink Swann saw him as a Managing Director of Investment Banking, instrumental in expanding their west coast operations. Prior to this, he held senior positions at Morgan Stanley, Credit Suisse First Boston, and Deutsche Banc Alex. Brown, where he honed his expertise in global healthcare investment banking.